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Use of randomisation in clinical trials:
a survey of UK practice
Gladys C McPherson1*, Marion K Campbell1 and Diana R Elbourne2
Abstract
Background: In healthcare research the randomised controlled trial is seen as the gold standard because it ensures
selection bias is minimised. However, there is uncertainty as to which is the most preferred method of
randomisation in any given setting and to what extent more complex methods are actually being implemented in
the field.
Methods: In this paper we describe the results of a survey of UK academics and publicly funded researchers to
examine the extent of the use of various methods of randomisation in clinical trials.
Results: Trialists reported using simple randomisation, permuted blocks and stratification more often than more
complex methods such as minimisation. Most trialists believed that simple randomisation is suitable for larger trials
but there is a high probability of possible imbalance between treatment groups in small trials. It was thought that
groups should be balanced at baseline to avoid imbalance and help face-validity. However, very few respondents
considered that more complex methods offer any advantages.
Conclusions: This paper demonstrates that for most UK trialists the preferred method of randomisation is using
permuted blocks of varying random length within strata. This method eliminates the problem of predictability
while maintaining balance across combinations of factors. If the number of prognostic factors is large, then
minimisation can be used to provide treatment balance as well as balance over these factors. However, only those
factors known to affect outcome should be considered.
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Background
The randomised controlled trial is widely regarded as
the principal method for obtaining a reliable evaluation
of treatment effectiveness of healthcare interventions.
Randomised controlled trials work on the principle of
random allocation – that is, unbiased allocation means
we can be confident that any observed differences be-
tween treatment groups are due to the treatments being
examined rather than due to any inherent differences
between the groups [1].
Random allocation to treatments is used to ensure that
patients in each treatment group will have similar distri-
butions of characteristics, permits the use of probability
theory to express the likelihood that the response to
treatment is due to chance, and should not allow the
next treatment allocation to be known in advance of the
patient's entry into the trial.
Randomisation is a method of eliminating bias in the
way that treatments are allocated to patients, but it does
not guarantee that the characteristics of the groups will
be completely balanced; if imbalance does occur, how-
ever, it will have occurred by chance rather than by the
introduction of some systematic bias [2]. Some factors
are known in advance to be important risk factors asso-
ciated with the outcome of the patient. Some researchers
believe that imbalance in these prognostic variables
could have a marked effect on the results of a trial and
on their credibility, in that it may be difficult to attribute
observed differences to the treatments under test. While
it is possible to modify the statistical analysis to take ac-
count of any differences between groups at baseline,
some authors have indicated it is preferable to control
for potential imbalance at the design stage [3,4].
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There are four main classes of randomisation proced-
ure available to the trialist when designing a trial:
complete (simple) randomisation, restricted randomisa-
tion, covariate-balancing randomisation and response-
adaptive randomisation (Table 1). These classes all have
different properties and influence treatment assignment
in different ways. Despite this range, it is often not clear
which method should be implemented for a specific
trial.
In 1997 Assman and colleagues evaluated the alloca-
tion methods used in a sample of 50 trials published in
four leading journals (British Medical Journal, The Lan-
cet, Journal of the American Medical Association, and
New England Journal of Medicine) [5]. They found that
30% used random permuted blocks, 6% minimisation,
2% simple randomisation and 44% did not specify the
method used. In 2000 Hewitt and Torgerson reviewed
232 trials published in the same four journals [6]. At that
time 50% used permuted blocks, 7% minimisation, 9%
simple randomisation and the method used was unclear
in 34%.
The aim of this study was therefore to determine the
most commonly used method(s) of randomisation
among a population of UK academics and publicly
funded researchers working in the field of clinical trials
and to investigate the extent of use of dynamic alloca-
tion methods such as minimisation.
Methods
Survey population
The survey was sent out at two time points: the primary
survey was sent out in 2003, and a follow-up survey was
sent out in 2011 to assess for any changes in opinions
and practice over time. The same survey instrument was
sent out at both time points (see Additional file 1).
In 2003 the Directory of Academic Statisticians [7],
which was the most comprehensive directory of statisti-
cians and methodologists working in academic research
in the UK at that time, was selected as the sampling
frame for statisticians and researchers working in the
field of clinical trials.
Within the Directory, people who identified them-
selves with the following categories of research interest
were selected: health, healthcare, health service research,
health statistics, health technique assessment, medical
statistics, clinical trials and randomisation. The initial
search yielded 527 people. The full text entry for each
person was examined and this led to the removal of 158
people whose areas of expertise were subsequently deter-
mined to be not relevant – for example, decision sup-
port systems in the National Health Service; analysis of
finance and health data; social statistician (crime, educa-
tion, health, poverty, race) – resulting in a target survey
population of 369. A further two statisticians who were
known to have a specific interest in randomisation
methods but who were not listed in the Directory were
also included as part of the survey population. This gave
a survey population of 371 that included known experts
in the field and representatives from all major UK trials
centres.
The questionnaire was sent out together with an ac-
companying letter explaining the purpose of the survey.
The questionnaire was printed on yellow paper as there
was some evidence that paper colour could enhance re-
sponse rates [8]. A reference number was included on
the questionnaire in order to track responses, but this
was removed by two people in order to preserve ano-
nymity. Recipients were requested to pass the question-
naire to another researcher if it was not relevant to
themselves. No reminders were sent out as the question-
naire was intended to be anonymous.
In January 2011 the survey was sent out a second time
to see whether practice had changed in the intervening
period. By 2011 the structure of trials support had chan-
ged radically in the UK with the establishment of formal
clinical trials units, which are required to be registered
with the UK Clinical Research Collaboration. Each trials
unit has a named information specialist lead (who will
generally be the first point of contact for randomisation
services). Reflecting this change, the survey was this time
sent (by email) to the information specialist for each
registered trials unit. Questionnaires were sent to 48
Table 1 Four main classes of randomisation procedure
Class Procedure
Simple randomisation Each patient has a known chance, usually equal, of being given each treatment and the treatment to be given cannot
be predicted in advance. The simplest method is tossing a coin, but one can also use random tables or a random
number generator on a calculator or computer.
Restricted randomisation Imposing specific constraints on the randomisation process (for example, random permuted blocks) with a view to
ensuring balance in the number of patients allocated to each treatment.
Covariate-balancing
randomisation
Often it is desirable not only to achieve similar numbers of patients in each treatment group but also to ensure that
patient groups are similar with respect to important prognostic factors such as age or gender. A number of
mechanisms have been put forward to ensure balance across important prognostic factors – the most common of
these include stratification and minimisation.
Response-adaptive
randomisation
The treatment assignments depend upon previous patient responses to treatment.
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registered trials unit statisticians (70 members) and in-
formation specialists (62 members) on the UK Clinical
Research Collaboration mailing lists. As before, no
reminders were sent to nonresponders.
Data analysis
Data were analysed descriptively using numbers and per-
centages for binary variables. Responses to open-text
boxes were categorised into common themes by the lead
author (GCM). No ethical approval was required or
sought.
Results
Of the 371 questionnaires sent out in 2003, 185 (50%)
were returned – 103 (56%) of these had some experience
of setting up the randomisation for a clinical trial and
are used in the analysis. Of the 132 questionnaires sent
out in 2011, 15 (11%) questionnaires were returned.
Results are presented for the combined survey popula-
tion unless there were observed differences between the
time points.
Opinions about and use of different statistical
randomisation methods
In 2003, 52% of respondents had used minimisation but
stratification, permuted blocks and simple randomisa-
tion were more often used (Table 2). Many respondents
used more than one method in different trials. In 2011
there was an increase in the proportion reporting having
used minimisation (87%), comparable with stratification
and permuted blocks.
When asked which methods they would use for small
trials, 61 (52%) indicated that they would use permuted
blocks, 22 (19%) stratification and 30 (25%) minimisa-
tion. When asked about stratification, 43% wrote that
the optimum number of strata was dependent upon the
size of trial. For those willing to put a figure to this, the
values ranged from 1 to 100 (interquartile range = 4, 9).
Twenty per cent stated that the number of strata should
be limited so that the expected number of participants
in each stratum would not be too small: anywhere be-
tween 10 and 50 participants or 5 to 10% of cases. Only
one person gave Therneau’s formula [9]:
No:of strata < N=blocksize and maybe
No:of strata < N= blocksize2ð Þ
Of those respondents who indicated that assignment
of patients to treatment groups should take account of
prognostic factors to show balance at baseline (n=67),
the most common reasons given were that it avoids im-
balance (n = 18) and that it helps face-validity (n = 13).
Other reasons given were that it achieves a gain in effi-
ciency (n = 5), achieves more precision in treatment
effect estimate (n = 4) or that it allows for simple ana-
lysis later (n = 3). Those who disagreed that assignment
should take account of prognostic factors (n = 18) main-
tained that adjusted analysis sorts out most of the imbal-
ance, it is not necessary for large trials and that it is best
left to chance.
Opinions about and use of minimisation
Fifty-seven per cent of respondents had used the method
of minimisation. Respondents indicated that the method
seemed to work and most would use it again. The fol-
lowing methods were reported as being used to reduce
the predictability of the next assignment: do not declare
factors in the trial protocol; add in other irrelevant fac-
tors to provide noise; allocate the first block of about 20
patients (either some random number or 10% have been
suggested) by permuted blocks or simple randomisation,
and then use minimisation with a randomisation ratio of
0.75:0.25 (or 80/20); use blocking, and then restricted
randomisation within each block; use centre as a mini-
misation factor in multicentre trials; use a probability
between 0.5 and 1 for allocation; or alternate between
simple randomisation/minimisation for small open trials.
When asked what was an appropriate level of random-
ness to use in minimisation, most respondents suggested
a probability of from 0.66 to 0.95, with most saying that
this level should be fixed throughout the life of the trial.
Twenty-two respondents reported using values between
0.75 and 0.95, and seven had used values lower than
0.75. Seventeen respondents always used the method of
Taves [10] with probability of assignment P= 1. Only
one person always retained a random element in mini-
misation. One person had conducted a trial where the
level of randomness was not fixed, but four others
thought that it might be a good idea to vary
randomness.
When asked about the number of factors that would
sensibly be included as minimisation factors, most
respondents felt that this was dependent on the size of
the trial. However, suggested rules of thumb included
that only known (evidence-based) prognostic variables
should be used and more than 10 is generally seen to be
too many, with more than five or six variables making it
Table 2 Use of different randomisation methods
Method used 2003 2011 Total
(n= 103) (n = 15) (n = 118)
Stratification 86 (84%) 13 (87%) 99 (84%)
Permuted blocks 82 (80%) 13 (87%) 95 (81%)
Simple randomisation 68 (66%) 10 (67%) 78 (66%)
Minimisation 54 (52%) 13 (87%) 67 (57%)
Other methods 10 (10%) 2 (13%) 12 (10%)
Data presented as n (%).
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tricky to test the programming. Nine respondents would
not set a limit on the number of factors, and 13 would
set a limit of four variables or less.
Sixty-six per cent of those who had used minimisation
adjusted for the minimisation factors using covariate ad-
justment as appropriate (40% always, 25% sometimes)
through analysis of covariance (ANCOVA), multiple re-
gression, logistic regression or Cox's regression. There
was a suggestion to perform both unadjusted and un-
adjusted analyses.
The most common problem encountered when using
minimisation was programming difficulty or errors, and
a few respondents stressed the importance of finding ap-
propriate purpose-written software. It was observed that
overall treatment imbalance can result if stratifying by
centre or clinician, and two respondents mentioned
checking for balance.
Use of other forms of constrained randomisation
Respondents were asked about their use of other (less
common) randomisation methods, including those of
Atkinson [11], Titterington [12], Signorini and collea-
gues [13] and Klotz [14]. Forty-nine (42%) respondents
had heard of Atkinson’s method but only one person
had ever used it, saying the method did not work and
they would not use it again. Although 25 (21%) respon-
dents had heard of Titterington’s method and 13 (11%)
had heard of Klotz’s method, no-one had ever used
them. Of the 22 (19%) people who had heard of Signori-
ni’s method, four had used the method and it had
worked but two would not use the method again be-
cause they perceived it to be not as good as minimisa-
tion and not as easy to use.
Opinions on choosing a randomisation method
The most important factor when choosing a randomisa-
tion method was seen as the size of the trial. The general
advice was to keep it simple and the most common
problem was identification of prognostic factors and lim-
iting their number. Other important factors included the
practicality of the method, maintaining blindness, im-
portance of prognostic factors, number of centres, size
of trial, length of trial and reducing predictability.
Ninety-eight (83%) respondents replied to the open
text question about giving general advice to someone
choosing a randomisation scheme. The five most com-
mon themes are listed in Table 3.
Problems encountered when setting up randomisation
schemes
Eighty-nine (75%) respondents replied to the open text
question outlining the most common problems encoun-
tered when setting up randomisation schemes (Table 4).
Web-based randomisation
In 2003, 80% of respondents had never used Web-based
randomisation systems although they would possibly use
them in the future. In 2011 only one respondent had
never used them and 11 (73%) had used them several
times. The biggest problems were thought to be lack of
expertise and security. Other problems to be overcome
include access to the Web, speed and reliability of ac-
cess, lack of willingness in centres, telephone methods
being preferred and trust in those performing the
randomisation.
Future directions
Most respondents thought that minimisation is likely to
be the most popular randomisation method in the fu-
ture, with the use of a random element to avoid the pos-
sibility of prediction of treatment allocation, followed by
permuted blocks. However, this was not a consensus
view as the stated views of experts within the survey
population ranged from ‘do not be misled by the hype
surrounding minimisation – it is most emphatically
Table 3 General advice when choosing a randomisation
scheme
2003 2011 Total
(n= 103) (n= 15) (n= 118)
Keep it simple 31 (30%) 4 (27%) 35 (30%)
Consider important prognostic
factors only (keep to a minimum)
24 (23%) 7 (47%) 31 (26%)
Limit predictability 10 (10%) 2 (13%) 12 (10%)
Speak to an experienced
statistician/expert
9 (9%) 0 (0%) 9 (8%)
Use minimisation if possible 8 (8%) 3 (20%) 11 (9%)
Data presented as n (%).
Table 4 Problems encountered when setting up
randomisation schemes
2003 2011 Total
(n = 103) (n = 15) (n = 118)
Identification of/limiting prognostic
factors/strata
11 (11%) 4 (27%) 15 (13%)
No problems 10 (10%) 2 (13%) 12 (10%)
Maintaining blindness/allocation
concealment
10 (10%) 0 (0%) 10 (8%)
Costs of/problems with commercial
services/telephone randomisation
6 (6%) 0 (0%) 6 (5%)
Ignorance or human mistakes 5 (5%) 1 (7%) 6 (5%)
Testing and monitoring 5 (5%) 1 (7%) 6 (5%)
Problems with/unavailable computer
programs
5 (5%) 0 (0%) 5 (4%)
Patients randomised out of
order/misallocation
5 (5%) 0 (0%) 5 (4%)
Drug supplies/stock management 3 (3%) 1 (7%) 4 (3%)
Data presented as n (%).
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NOT the platinum standard’ to ‘I would favour mini-
misation because of its advantages not just for small
trials but also for large trials in which analysis within
subgroups would be based on better balance’.
Discussion
Simple randomisation
The results of this survey have shown that trialists are
currently using simple randomisation less often than
permuted blocks, stratification and minimisation. The
size of trial considered too small for simple randomisa-
tion ranged from <50 to <1,000, although some trialists
surveyed believed that simple randomisation was suit-
able for any size of trial.
Within the wider literature, there is evidence that sim-
ple randomisation is suitable for larger trials [3,15-17]
but there is a high probability of possible imbalance be-
tween treatment groups in trials of up to 500. Simula-
tions showed that imbalance can occur often in small
trials with <100 participants (for example, >80% of occa-
sions), but imbalance rarely occurs in trials with ≥1,000
participants [15]. Pocock and Simon also suggested that
simple randomisation was only to be recommended for
larger trials (say >200 participants), and cautioned that
even in large trials problems may occur if one intends to
analyse early results (say for data monitoring) [16].
Stratification
Forty-three per cent of trialists wrote that the number of
strata to be used should depend on the size of trial.
There was no general consensus on the number of strata
that were considered too many, with suggested values
between 1 and 100.
Pocock and Simon stated that it is seldom advisable to
stratify on more than three or four variables and the size
of the trial is the most important factor in deciding how
many stratification variables are feasible [16]. Peto and
colleagues dismiss stratification as a complication ren-
dered unnecessary by the development of methods of
analysis that adjust for covariates [18].
Pocock and Simon used simulations to show that in-
creasing imbalance between treatment groups can arise
due to increasing number of strata with incomplete ran-
domised blocks [16]. Signorini and colleagues asserted
that using a randomised block design presented a possi-
bility of the overall trial having large differences in num-
ber of patients in each treatment, even though each
stratum has more or less equal numbers on each treat-
ment [13]. This leads to a loss in efficiency in the ana-
lysis. The same problem can arise when employing a
randomisation scheme using minimisation with stratifi-
cation by centre or clinician, although International
Conference on Harmonisation (ICH) guidelines still rec-
ommend this [19].
Balancing prognostic factors at baseline
More than one-half of the trialists surveyed thought that
groups should be balanced at baseline. The primary rea-
sons given were that it helps face-validity and the ana-
lysis is simpler. The suggested limit on the number of
prognostic factors ranged from 2 to 10, and some trial-
ists would not set any limit.
There is controversy, especially among statisticians, as
to whether prognostic factors should be used in assign-
ment to treatment [20]. There are two main viewpoints:
prognostic factors should be used to assure that patients
assigned to the two arms show close balance in progno-
ses at baseline; or random assignment should be used
without regard to prognostic factors, as fair comparison
of treatment effect can be achieved through statistical
adjustment of results.
Armitage and Gehan concluded that in a small to
moderate-sized trial (≤100 patients) results might be in-
valid if prognostic factors are not used [21]. Compari-
sons between treatments should be made between
groups that are comparable with respect to prognostic
factors. Similarly, Rovers and colleagues suggested that
investigators should always consider balanced allocation
for a low number of patients [22]. They stated that, in a
trial with 100 to 200 patients, substantial differences can
occur in baseline characteristics if simple randomisation
is used; if these differences can be measured, then they
can be corrected to some degree in the analysis. If the
number of patients decreases or the number of prognos-
tic variables or categories increases, then the resulting
imbalance could invalidate results.
The Committee for Proprietary Medicinal Products
state that stratification for more than a few prognostic
factors is not always possible [23]. They describe techni-
ques of dynamic allocation such as minimisation that
are often used to balance across several factors simultan-
eously as highly controversial even if deterministic
schemes are avoided. They therefore strongly advise
against the use of such methods. When deterministic
schemes are used, the Committee for Proprietary Medi-
cinal Products also suggest that the factors used in the
allocation scheme should also be included as covariates
in the analysis (although whether the analysis adequately
reflects the randomisation scheme also remains contro-
versial). They also state that if a multicentre trial is not
stratified by centre then the reasons for not doing this
should be explained and justified in the protocol.
Predictability
Nineteen per cent of trialists who had used minimisation
were very concerned that the method was largely deter-
ministic and 57% were only mildly concerned. Twenty-
eight per cent were not concerned at all in 2003, but in
2011 this number had dropped to zero. Among the
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trialists surveyed, strategies for reducing the predictabil-
ity of next assignment included not declaring the factors
in the protocol, adding in other factors to produce noise,
not stratifying by centre and alternating between mini-
misation and simple randomisation. When using a ran-
dom element, the level of randomness chosen ranged
from 0.66 to 0.95.
When choosing a balanced allocation method the
probability of performing the prescribed allocation
should be large enough to control imbalances in strata
but small enough to prevent selection bias through pre-
diction of next treatment [24]. The use of a random
element (probability of assignment P<1) is supported by
ICH E9 [19], which also states that factors on which ran-
domisation has been stratified should be accounted for
later in the analysis. Gore recommends a value for prob-
ability of assignment of 0.75 [25]. In a multicentre trial,
predictability is not a problem unless stratifying by
centre as recommended by ICH E9 guidelines, when all
centres are essentially independent or they are not aware
of the bands used [20].
The Food and Drug Administration also consider
minimisation not to be random and recommend the in-
corporation of a random element [26]. However, a mini-
misation procedure to allocate treatment that does not
allow investigators to predict the next treatment alloca-
tion would yield a properly randomised trial [16].
Randomised block design can also be highly predict-
able [13] since each block must contain equal numbers
of patients on each treatment. The block size should be
hidden from investigators but can sometimes be
deduced from previous assignments if the block size is
fixed. Therefore it is better to use random block sizes.
Analysis
In 2003 almost one-quarter of those using minimisation
never adjusted for prognostic factors in the analysis, be-
lieving that if the minimisation has worked then there
should be no need to do so. In 2011 this number had
dropped to zero. Forty per cent indicated that they al-
ways adjusted for the minimisation factors in the
analysis.
Taves maintains that clinical trials managed by mini-
misation should use ANCOVA for statistical comparisons
[10]. Lachin and colleagues indicate for minimisation that
the statistical analysis must incorporate adjustments for
the covariates employed in the design in order to yield
tests of proper size [17].
Forsythe and Stitt studied analysis of variance and
ANCOVA in a simulation study of a small clinical trial
and found some evidence that ANCOVA with minimisa-
tion was more powerful than ANCOVA with simple ran-
domisation [27]. They showed that using minimisation
without adjusting for covariates in the subsequent
analysis distorted the significance level and the power of
the test. However, they reported that other studies im-
plied that the effects of stratifying by a covariate and
then ignoring it in the analysis may not be severe. It may
be that introducing randomness into a systematic design
reduces such accidental bias, but further research is
needed.
Vaughan Reed and Wickham discussed the validity of
using an unadjusted analysis [28]. They maintained that
the errors introduced by using an unadjusted analysis
for a deterministic allocation method were likely to be
less than the errors resulting from imbalance between
treatment groups that might occur using simple ran-
domisation. They maintained that serious imbalance be-
tween treatment groups undoubtedly causes problems
with analysis and interpretation.
Strengths and limitations of the study
Sampling frame
For the original sampling frame, the Directory of Aca-
demic Statisticians is not compulsory so the list cannot
claim to be exhaustive. The declared areas of interest are
also voluntary and therefore relevant statisticians may
have been missed using this source. Some research cen-
tres have dedicated programmers who set up randomisa-
tion schemes, and these people would not be included in
the register. Although the second round of the survey
did target these people, the response rate was very low –
so it is difficult to draw any definite conclusions from
these responses alone. Some individuals may also pos-
sibly have responded at both time points because the
first survey was anonymous. Views from the pharma-
ceutical industry are not represented here at all.
Question formats
A mix of open-text and multiple-choice questions were
included in the survey. Every effort was made to formu-
late the questions so as to elicit unbiased responses.
However, some respondents queried the wording of
some of the questions, perhaps reflecting the heated de-
bate that was ongoing amongst clinical trialists, aca-
demics and governing bodies at the time the survey was
sent out.
Conclusions
From this survey it was apparent that if the number of
important prognostic factors and layers within these is
sufficiently small, then the preferred method of random-
isation (agreed by most trialists and the ICH) is per-
muted blocks of varying random length within strata.
This method reduces the problem of predictability and
at the same time balances across combinations of fac-
tors. If the number of prognostic factors is large, then
minimisation can be used to provide treatment balance
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as well as balance over these factors. However, only
those factors known to affect outcome should be
considered.
Trialists believe that keeping the randomisation
method as simple as possible will reduce time, cost and
programming errors. More complex algorithms may in-
crease costs and errors, prove difficult to understand
and may not prove to be less predictable. Whatever
method is chosen, consideration should be given to
using simulations to test the method first to ensure that
the algorithm is correct, achieves balance and is not
predictable.
Survey respondents stated that the method of random-
isation should depend on the context of the study, the
objectives of the study and the resources available. One
method may not be suitable for all trials.
Survey respondents predict that minimisation will
probably become more widely used in the future along
with increased use of Web-based and telephone-based
systems. However, very few respondents considered that
more complex methods of randomisation offer any
advantages.
Additional file
Additional file 1: Current use of statistical randomisation methods
in clinical trials. Survey instrument which was sent out in 2003 and
2011.
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